Compare Regeneron Pharmaceuticals Inc (REGN) vs United Parcel Service Inc (UPS) Price & Performance

Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.

The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.

UPS stock trades at $116.34, down 1.17% on the day, with a bullish technical signal from moving averages and neutral oscillators. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 results due July 28, 2026. Revenue declined to $88.66 billion in 2025, but cost controls supported a net margin of 5.94% and strong ROE of 33.41%. The company maintains solid cash flow from operations of $8.45 billion and recently paid a $1.64 dividend.

Outlook is mixed: cost-cutting and potential Q2 earnings beat offer upside, but revenue pressure and Amazon's logistics expansion pose risks. Analysts are cautiously optimistic with a $112 consensus target, slightly below current price. Key investor focus is on Q2 results and updated guidance for second-half 2026 inflection point prospects.